Summary

Other Scenarios:

Buyer: Gilead Sciences, Inc. (GILD) Last Price: 80.83 Market Cap.: 37.74B
Target: MedImmune, Inc. (MEDI) Last Price: 57.94 Market Cap.: 13.84B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 884
Biopharmaceuticals 342
Cardiovascular System   16
Vascular Disorders   1
Dermatology   7
Phase I/Phase II Clinical Stage Products   0
Digestive System   3
Liver Disorders   0
Phase I/Phase II Clinical Stage Products   0
Research/Preclinical Stage Products   0
Hematology   4
Research/Preclinical Stage Products   0
Immunology 10
Immune Deficiency Disorders   0
Phase I/Phase II Clinical Stage Products 0
Research/Preclinical Stage Products   0
Infectious Diseases 35
Mycological (Fungal) 0
Phase I/Phase II Clinical Stage Products 0
Protozoal   0
Research/Preclinical Stage Products 0
Viral 8
Musculoskeletal System   4
Research/Preclinical Stage Products   0
Oncology 79
Dermatology   0
Head/Neck Cancer   0
Phase I/Phase II Clinical Stage Products   0
Research/Preclinical Stage Products   0
Respiratory System/Thoracic   0
Urology   1
Ophthalmology   6
Degenerative Disorders   2
Respiratory System 6
Lower Respiratory Tract Disorders (Lung Disorders)   4
Phase I/Phase II Clinical Stage Products   0

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 19)
  • Hepsera (Adefovir Dipivoxil)
  • Viread (Tenofovir Disoproxil Fumarate)
  • Emtriva (Emtricitabine)
  • Tamiflu (Oseltamivir)
Target (Total: 36)
  • RespiGam (Respiratory Syncytial Virus Immune Globulin Intravenous)
  • Numax (Anti-RSV MAb)
  • Synagis (Palivizumab)
  • Liquid Synagis (Palivizumab)
Buyer
  • Darusentan
  • Ambrisentan
  • Flolan (Epoprostenol Sodium)
  • Viread (Tenofovir Disoproxil Fumarate)
Target
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • MEDI-545 (Anti-Interferon Alpha Monoclonal Antibody)
  • MDX-1103 (Human Antibodies)
  • MEDI-546 (Anti-Type 1 Interferon Receptor Monoclonal Antibody)

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 1)
  • Genelabs Technologies (GNLB)
Target (Total: 17)
  • Micromet Inc. (MITI)
  • Infinity Pharmaceuticals Inc. (INFI)
  • Critical Therapeutics, Inc. (CRTX)
  • Option Care, Inc. (OPTN)
Buyer (Total: 4)
  • Cardinal Health, Inc. (CAH)
  • McKesson Corporation (MCK)
  • AmerisourceBergen Corp. (ABC)
  • OSI Pharmaceuticals, Inc. (OSIP)
Target (Total: 10)
  • AmerisourceBergen Corp. (ABC)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • Abbott Laboratories (ABT)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 2,515 2,359
Revenue Per Employee 1,636,913.0 976,913.8
Total Revenue 1,028.4 574.8
Total Expenses 468.3 342.4
Other Revenue 0.0 0.0
Cost of Revenue 171.6 115.5
SG&A Expense 166.6 147.1
Research & Development 130.1 79.5
Other Operating Expense 0.0 0.3
Operating Income 560.1 232.4
Unusual Income 0.0 0.0
LT Debt to Capital 35.3 44.29
Fwd P/E 26.35 64.37
Fwd P/Rev 9.16 9.51
Book Value 2,382.7 1,464.4
Curr Portion of LTD/Cap Lease 0.3 0.0

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals > Infectious Diseases > Viral

Target

Focused (): *Healthcare > Biopharmaceuticals > Infectious Diseases > Viral

Business Description

Buyer

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics in areas of unmet medical need. The Company primarily focuses on the development and commercialization of human therapeutics for life threatening diseases. Gilead?s products include Truvada (tenofovir disoproxil fumarate and emtricitabine), Viread, Atripla (efavirenz 600 milligram/emtricitabine 200 milligram/tenofovir disoproxil fumarate 300 milligram), Emtriva, Hepsera (adefovir dipivoxil), AmBisome (amphotericin B liposome for injection), Vistide (cidofovir injection) and Flolan (epoprostenol sodium). The Company receives royalties from other products, including Tamiflu (oseltamivir phosphate), Macugen (pegaptanib sodium injection) and DaunoXome (liposomal daunorubicin injection). Gilead has operations in North America, Europe and Australia. In August 2006, the Company acquired Corus Pharma, Inc. In November 2006, Gilead acquired Myogen, Inc. and Raylo Chemicals Inc.

Target

MedImmune, Inc. is a biotechnology company focusing its efforts on the therapeutic areas of infectious disease, cancer and inflammatory disease. The Company primarily develops monoclonal antibodies and vaccines. MedImmune markets three products: Synagis (palivizumab) and FluMist (Influenza Virus Vaccine Live, Intranasal) to help prevent two common respiratory infectious diseases, and Ethyol (amifostine) to help reduce adverse side effects of certain anti-cancer chemotherapies and radiotherapies. The Company is also developing a pipeline of product candidates for potential commercialization. MedImmune operates facilities in the United States and Europe to manufacture and distribute one or more components of each of its products. The Company has established clinical, research, development, manufacturing and commercialization collaborations with other companies and organizations. In December 2006, MedImmune sold all rights to the CytoGam product line and related assets to ZLB Behring AG.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 84.69 76.35
Operating Margin % -16.96 11.19
Quick Ratio 2.28 3.64
Current Ratio 3.44 3.98
Coverage Ratio -0.2 0.61
Total Assets 4,615.4 3,033.5
Return on Equity % -43.87 11.04
Return on Assets % -22.65 5.33
Cash+ ST Inv. Per Share 1.92 4.3
Total Debt 1,300.3 1,164.1
Total Debt to Equity % 54.57 79.49
Total Debt to Tangible Equity % 57.76 91.37
Debt to Asset % 28.17 38.37

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Cardiovascular System  
Vascular Disorders  
Hypertension  
Endothelin Receptor Antagonists
Therapeutics that treat hypertension by blocking the action of endothelin, which prevents/reduces constriction of the blood vessels.

Buyer Products:

  • Darusentan
  
Primary Pulmonary Hypertension  
Endothelin Receptor Antagonists
Therapeutics that treat hypertension by blocking the action of endothelin, which prevents/reduces constriction of the blood vessels.

Buyer Products:

  • Ambrisentan
  
Prostacyclins
Therapeutics that relieve pulmonary hypertension by causing vasodilation of the pulmonary blood vessels.

Buyer Products:

  • Flolan (Epoprostenol Sodium)
  
Dermatology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • MEDI-545 (Anti-Interferon Alpha Monoclonal Antibody)
  
Digestive System  
Liver Disorders  
Hepatitis  
Hepatitis B  
Chronic  
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat hepatitis by inhibiting the action of reverse transcriptase, an enzyme necessary for DNA synthesis using an RNA template.

Buyer Products:

  • Viread (Tenofovir Disoproxil Fumarate)
  • Hepsera (Adefovir Dipivoxil)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Emtriva (Emtricitabine)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • NS4A Antagonists
  • GS 9190 (HCV Polymerase Inhibitor)
  • HCV Protease And Polymerase Inhibitors
  
Hematology  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Small Molecule Therapeutics
  
Immunology
Immune Deficiency Disorders  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Viread (Tenofovir Disoproxil Fumarate)
  • Truvada (Tenofovir Disoproxil Fumarate/Emtricitabine)
  • Emtriva (Emtricitabine)
  
Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • GS 9137 (HIV Integrase Inhibitor)

Target Products:

  • MEDI-545 (Anti-Interferon Alpha Monoclonal Antibody)
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Target Products:

  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • MDX-1103 (Human Antibodies)
  • MEDI-546 (Anti-Type 1 Interferon Receptor Monoclonal Antibody)
  • Anti-Chitinase MAb
  • Anti-CD19/Anti-CD20/Anti-CD22 Monoclonal Antibodies
  • Anti-HMGB1 Monoclonal Antibody
  • Anti-ICOS MAbs
  
Infectious Diseases
Mycological (Fungal)
Antifungal Agents
Broad Spectrum  
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections by increasing permeability of the cell wall causing leakage of cellular contents.

Buyer Products:

  • AmBisome (Amphotericin B)
  
Narrow Spectrum
Nervous System  
Cryptococcal Meningitis  
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the lining of the brain and spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • AmBisome (Amphotericin B)
  
Respiratory System  
Pneumocystis Carinii Pneumonia (PCP)  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat infections of the lungs of immunocompromised patients caused by Pneumocystis carinii by blocking the action of dihydrofolate reductase.

Target Products:

  • Neutrexin (Trimetrexate Glucuronate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • GS 9137 (HIV Integrase Inhibitor)

Target Products:

  • RSV/Anti-Human Metapneumovirus (hMPV)/Parainfluenzavirus (PIV) Vaccine
  • Anti-Human Metapneumovirus Monoclonal Antibody
  • RSV Vaccine
  • Epstein-Barr Virus (EBV) Vaccine
  • Streptococcus pneumoniae Vaccine
  • Intranasal H5N1 Influenza Vaccine
Protozoal  
Antiprotozoal Agents  
Narrow Spectrum  
Visceral Leishmaniasis  
Polyene Macrolide Antibiotics
Therapeutics that treat infections characterized by Leishmania in macrophages by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • AmBisome (Amphotericin B)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • Tamiflu (Oseltamivir)
  • Inhaled Therapeutics
  • Small Molecule Therapeutics

Target Products:

  • EphA2 Antagonists
  • Streptococcus pneumoniae Vaccine
  • Anti-Candida HP Monoclonal Antibody
  • Anti-Staphylococcal HP Monoclonal Antibody
  • Anti-RSV Drug
  • Third Generation Respiratory Syncitial Virus (RSV) Monoclonal Antibody
  • Anti-HMGB1 Monoclonal Antibody
Viral
DNA Viruses  
Hepadnavirus  
Hepatitis B  
Chronic  
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months by blocking enzyme essential for viral DNA synthesis.

Buyer Products:

  • Hepsera (Adefovir Dipivoxil)
  • Viread (Tenofovir Disoproxil Fumarate)
  • Emtriva (Emtricitabine)
  
RNA Viruses
Orthomyxovirus  
Influenza A  
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza A virus by preventing the release of new viruses from infected cells.

Buyer Products:

  • Tamiflu (Oseltamivir)
  
Influenza B  
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza B virus by preventing the release of new viruses from infected cells.

Buyer Products:

  • Tamiflu (Oseltamivir)
  
Paramyxovirus  
Respiratory Syncytial Virus (RSV)  
Immunoglobulins
Therapeutics that treat viral infections in the respiratory tracts of infants with a variety of specific protein that neutralizes the virus.

Target Products:

  • RespiGam (Respiratory Syncytial Virus Immune Globulin Intravenous)
  
Monoclonal Antibodies
Therapeutics that treat viral infections in the respiratory tracts of infants with a neutralizing protein that targets a specific site on the virus.

Target Products:

  • Numax (Anti-RSV MAb)
  • Synagis (Palivizumab)
  • Liquid Synagis (Palivizumab)
  
Retrovirus  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Viread (Tenofovir Disoproxil Fumarate)
  • Emtriva (Emtricitabine)
  • Truvada (Tenofovir Disoproxil Fumarate/Emtricitabine)
  
Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate)
  
Vaccines  
Viral  
Single Target  
Influenza (Flu)
Therapeutics that prevent or treat viral infections of the respiratory tract by producing or artificially increasing immunity to the Influenza virus.

Target Products:

  • FluMist (Influenza Virus Vaccine Live, Intranasal)
  • FluMist Refrigerated Formualtion (Influenza Vaccine Live, Intranasal)
  
Musculoskeletal System  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.

Target Products:

  • Anti-HMGB1 Monoclonal Antibody
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  
Oncology
Dermatology  
Kaposi`s Sarcoma  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of spindle cells by inhibiting a specific enzyme needed for transcription and replication of DNA.

Buyer Products:

  • DaunoXome (Liposomal Daunorubicin Injection)
  
Head/Neck Cancer  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treament for head and neck cancers.

Target Products:

  • Ethyol (Amifostine)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Target Products:

  • MT103/MEDI-538 (T-Cell Engager)
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • Intravenous IPI-504 (Hsp90 inhibitor)
  • Ethyol (Amifostine)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Target Products:

  • Anti-EphB4/Anti-EphrinB2 Antibodies
  • cMET Receptor Antagonists
  • EphA4 Agonists
  • Anti-CD19/Anti-CD20/Anti-CD22 Monoclonal Antibodies
  • Anti-ALK Monoclonal Antibody
  • EphA2 Antagonists
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • Hedgehog Antagonist
  • Anti-Chitinase MAb
  
Respiratory System/Thoracic  
Lung Cancer  
Non Small Cell Lung Cancer (NSCLC)  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treatment for cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma

Target Products:

  • Ethyol (Amifostine)
  
Urology  
Ovarian Cancer  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treatment for cancers of the ovaries.

Target Products:

  • Ethyol (Amifostine)
  
Ophthalmology  
Degenerative Disorders  
Retinitis  
AIDS-Related Cytomegalovirus (CMV) Retinitis  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Vistide (Cidofovir)
  
Respiratory System
Lower Respiratory Tract Disorders (Lung Disorders)  
Cystic Fibrosis (CF)  
Complications  
Bacterial Infections  
Antibacterial Agents (Antibiotics)  
Monobactams
Therapeutics that treat bacterial infections of the lung resulting as a complication of cystic fibrosis by inhibiting bacterial cell wall synthesis during active multiplication.

Buyer Products:

  • Inhaled Aztreonam Lysine
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Target Products:

  • BIW-8405 (IL-5 Monoclonal Antibody)
  • MEDI-528 (IL-9 Monoclonal Antibody)
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Pfizer Inc. n/a 185,773.425 9.98 12.27 3.78 3.88 6.62
Roche Holding Ltd. (ADR) n/a 152,846.074 23.37 19.55 4.38 3.77 6.56
GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Novartis AG (ADR) n/a 130,940.797 23.99 16.65 3.43 3.42 3.23
Genentech, Inc. n/a 81,094.091 33.82 28.67 8.00 6.85 9.67
AstraZeneca plc (ADR) n/a 77,549.535 12.55 12.58 2.84 2.73 8.20
Bristol Myers Squibb Co. n/a 60,537.680 38.78 21.16 3.42 3.01 16.56
Schering-Plough Corporation n/a 46,156.165 36.96 24.25 4.19 3.89 5.98
RegeneRx Biopharmaceuticals, Inc. n/a 94.038 n/a n/a 344.59 n/a 6.94
Buyer
  Pfizer Inc. n/a 185,773.425 9.98 12.27 3.78 3.88 6.62
Roche Holding Ltd. (ADR) n/a 152,846.074 23.37 19.55 4.38 3.77 6.56
Target
  Pfizer Inc. n/a 185,773.425 9.98 12.27 3.78 3.88 6.62
Johnson & Johnson n/a 181,816.951 17.62 15.46 3.28 2.98 15.54
Roche Holding Ltd. (ADR) n/a 152,846.074 23.37 19.55 4.38 3.77 6.56
GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Novartis AG (ADR) n/a 130,940.797 23.99 16.65 3.43 3.42 3.23
sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
Genentech, Inc. n/a 81,094.091 33.82 28.67 8.00 6.85 9.67
AstraZeneca plc (ADR) n/a 77,549.535 12.55 12.58 2.84 2.73 8.20
Amgen, Inc. n/a 68,453.847 22.37 14.31 4.64 4.51 14.25
Eli Lilly & Co. n/a 65,456.964 28.01 16.98 4.04 3.68 7.18
Bristol Myers Squibb Co. n/a 60,537.680 38.78 21.16 3.42 3.01 16.56
Schering-Plough Corporation n/a 46,156.165 36.96 24.25 4.19 3.89 5.98
Medarex, Inc. n/a 1,924.479 n/a -62.54 40.86 41.21 3.45
Alnylam Pharmaceuticals, Inc. n/a 634.071 n/a -10.80 22.30 20.99 3.37

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Genelabs Technologies 50.80% 71.357 n/a n/a 5.45 n/a 6.04
Target
  Micromet Inc. 19.00% 82.856 n/a -2.53 3.16 5.32 26.73
Infinity Pharmaceuticals Inc. 18.00% 208.108 n/a -9.56 8.71 9.09 3.43
Critical Therapeutics, Inc. 10.00% 104.389 n/a -3.05 7.30 4.67 2.25
Option Care, Inc. 9.50% 535.901 22.65 20.26 0.75 0.66 16.40
Seattle Genetics, Inc. 9.30% 564.933 n/a -14.03 46.30 29.38 6.92
PDL BioPharma Inc. 8.00% 2,877.777 n/a 73.88 6.67 5.94 24.10
Abbott Laboratories n/a 84,288.496 54.40 19.28 3.73 3.72 n/a
Baxter International Inc. n/a 37,709.816 24.84 21.71 3.54 3.43 8.34
Cardinal Health, Inc. n/a 26,906.163 19.93 20.66 0.31 0.31 7.77
Becton, Dickinson and Co. n/a 18,677.709 24.39 20.13 3.11 2.96 5.58
Medarex, Inc. n/a 1,924.479 n/a -62.54 40.86 41.21 3.45
Human Genome Sciences n/a 1,365.526 n/a -5.98 48.47 26.89 7.89
Applix, Inc. n/a 255.585 25.58 40.35 4.48 3.79 12.00
Dyax Corp. n/a 223.889 n/a -3.64 17.58 13.74 10.98
Cerus Corporation n/a 196.206 n/a -5.07 5.90 11.01 2.07
SM&A n/a 131.566 33.71 17.50 1.69 1.44 4.31
Avalon Pharmaceuticals, Inc. n/a 65.589 n/a -2.92 22.49 19.33 2.88

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Cardinal Health, Inc. 18.00% 26,906.163 19.93 20.66 0.31 0.31 7.77
McKesson Corporation 11.80% 18,039.456 19.76 18.84 0.19 0.18 5.76
AmerisourceBergen Corp. 11.80% 9,647.715 19.56 19.88 0.15 0.15 6.93
Buyer
  Cardinal Health, Inc. 18.00% 26,906.163 19.93 20.66 0.31 0.31 7.77
McKesson Corporation 11.80% 18,039.456 19.76 18.84 0.19 0.18 5.76
AmerisourceBergen Corp. 11.80% 9,647.715 19.56 19.88 0.15 0.15 6.93
OSI Pharmaceuticals, Inc. n/a 2,134.020 n/a 30.11 6.34 6.58 n/a
Target
  AmerisourceBergen Corp. 29.00% 9,647.715 19.56 19.88 0.15 0.15 6.93
McKesson Corporation 18.00% 18,039.456 19.76 18.84 0.19 0.18 5.76
Cardinal Health, Inc. 15.00% 26,906.163 19.93 20.66 0.31 0.31 7.77
Abbott Laboratories 12.00% 84,288.496 54.40 19.28 3.73 3.72 n/a
GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Merck & Co., Inc. n/a 109,945.758 23.81 17.14 4.78 4.69 6.80
Medco Health Solutions Inc. n/a 22,523.128 26.18 23.05 0.52 0.49 n/a
Option Care, Inc. n/a 535.901 22.65 20.26 0.75 0.66 16.40
GTC Biotherapeutics, Inc. n/a 90.373 n/a -2.74 9.66 12.98 3.21
Government - United States n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Novartis AG (ADR) n/a 130,940.797 23.99 16.65 3.43 3.42 3.23
Merck & Co., Inc. n/a 109,945.758 23.81 17.14 4.78 4.69 6.80
Cardinal Health, Inc. n/a 26,906.163 19.93 20.66 0.31 0.31 7.77
Medarex, Inc. n/a 1,924.479 n/a -62.54 40.86 41.21 3.45
Japan Tobacco, Inc. n/a n/a n/a n/a n/a n/a n/a
Buyer
  Pfizer Inc. n/a 185,773.425 9.98 12.27 3.78 3.88 6.62
Roche Holding Ltd. (ADR) n/a 152,846.074 23.37 19.55 4.38 3.77 6.56
Target
  GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Novartis AG (ADR) n/a 130,940.797 23.99 16.65 3.43 3.42 3.23
sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
Merck & Co., Inc. n/a 109,945.758 23.81 17.14 4.78 4.69 6.80
Abbott Laboratories n/a 84,288.496 54.40 19.28 3.73 3.72 n/a
Schering-Plough Corporation n/a 46,156.165 36.96 24.25 4.19 3.89 5.98
Baxter International Inc. n/a 37,709.816 24.84 21.71 3.54 3.43 8.34
Teva Pharmaceutical Industries Ltd (ADR) n/a 31,840.000 16.79 17.90 3.61 3.47 23.48
Cardinal Health, Inc. n/a 26,906.163 19.93 20.66 0.31 0.31 7.77
Medco Health Solutions Inc. n/a 22,523.128 26.18 23.05 0.52 0.49 n/a
Becton, Dickinson and Co. n/a 18,677.709 24.39 20.13 3.11 2.96 5.58
PDL BioPharma Inc. n/a 2,877.777 n/a 73.88 6.67 5.94 24.10
Medarex, Inc. n/a 1,924.479 n/a -62.54 40.86 41.21 3.45
Biosite Incorporated n/a 1,575.310 40.68 39.06 5.03 4.82 5.28
Human Genome Sciences n/a 1,365.526 n/a -5.98 48.47 26.89 7.89
Crucell N.V. (ADR) n/a 1,323.323 n/a -32.79 12.95 4.36 3.46
Seattle Genetics, Inc. n/a 564.933 n/a -14.03 46.30 29.38 6.92

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 3,361.7 1,353.6 4,715.3
Other Revenue 0.0 0.0 0.0
Total Revenue 3,361.7 1,353.6 4,715.3
Cost of Revenue 514.6 320.1 834.7
SG&A Expense 597.7 476.4 1,074.1
Depreciation & Amortization 0.0 0.0 0.0
Research & Development 425.6 440.5 866.1
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 13.6 13.6
Unusual Expense (Income) 2,394.1 -48.5 2,345.6
Total Expenses 3,932.0 1,202.1 5,134.1
Operating Income -570.3 151.5 -418.8
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 115.5 92.9 208.4
Other, Net 0.0 0.0 0.0
Income Before Taxes -454.8 244.4 -210.4
Income Taxes 590.5 82.7 673.2
Income After Taxes -1,045.3 161.7 -883.6
Net Income - Excl. Xord. Items -1,045.3 161.7 -883.6
Net Income - Incl. Xord. Items -1,045.3 161.7 -883.6
Income Avail. to Common -1,045.3 161.7 -883.6
Share Items
Basic Avg. Shares Outstanding 463.5 237.9 701.4
Basic EPS - Excl. Xord. Items n/a 0.68 -1.26
Basic EPS - Incl. Xord. Items n/a 0.68 -1.26
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 481.4 241.4 722.8
F.D. EPS - Excl. Xord. Items n/a 0.67 -1.22
F.D. EPS - Incl. Xord. Items n/a 0.67 -1.22
Balance Sheet
Assets
Cash and Equivalents 729.1 463.3 1,192.4
ST Investments 196.6 574.2 770.8
Accounts Receivable 692.1 280.6 972.7
Inventory 522.4 87.6 610.0
Prepayments and Advances 48.5 0.0 48.5
Other Current Assets 251.8 35.3 287.1
Current Assets 2,440.6 1,441.0 3,881.6
Accum D&A 0.0 0.0 0.0
PPE, Net 377.1 502.8 879.9
Goodwill & Intangibles 131.4 190.4 321.8
Long Term Investments 934.7 566.4 1,501.1
Other Assets 0.0 0.0 0.0
Other LT Assets 731.6 332.9 1,064.5
Total Assets 4,615.4 3,033.5 7,648.9
Liabilities
Accounts Payable 297.3 45.1 342.4
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 365.9 185.3 551.2
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 0.3 0.0 0.3
Other (Current) Liabilities 47.0 131.8 178.8
Current Liab. 710.5 362.2 1,072.7
LT Debt 1,300.0 1,164.1 2,464.1
Total LT Debt 1,300.0 1,164.1 2,464.1
Minority Interest (BS) 57.9 0.0 57.9
Other LT Liab. 164.3 42.8 207.1
Total Liabilities 2,232.7 1,569.1 3,801.8
Shareholders Equity
Common Stock 0.5 2.6 3.1
Additional Paid in Capital 2,885.3 2,713.7 5,599.0
Retained Earnings -498.0 -705.7 -1,203.7
Treasure Stock 0.0 -540.5 -540.5
Other Equity -5.1 -5.7 -10.8
Total Equity 2,382.7 1,464.4 3,847.1
Total Liab. & Equity 4,615.4 3,033.5 7,648.9
Shares Outstanding 465.5 237.7 703.2
Cash Flow
Operating Cash Flow
CF Net Income -1,045.3 161.7 -883.6
CF Depreciation 28.1 117.8 145.9
CF Amortization 19.6 0.0 19.6
CF Deferred Taxes -0.7 -11.5 -12.2
Other Non-Cash Items 2,713.8 -26.8 2,687.0
Change in Working Capital -228.8 -346.0 -574.8
Total Cash From Operating Activities 1,486.7 -104.8 1,381.9
Investing Cash Flow (not calculated)
Capital Expenditures -116.0 -145.6 -261.6
Other Investing Cash Flows -1,523.8 417.7 -1,106.1
Total Cash From Investing Activities -1,639.8 272.1 -1,367.7
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock -337.0 -179.8 -516.8
Purchase and Retirement of Debt 1,031.7 638.5 1,670.2
Other Financing Cash Flow -52.0 -310.6 -362.6
Total Cash From Financing Activities 642.7 148.1 790.8
Exchange Rate Effects -29.1 -0.1 -29.2
Net Change in Cash 460.5 315.3 775.8
Cash Taxes Paid 489.7 2.0 491.7
Cash Interest Paid 15.7 3.8 19.5